Three brand names dominate conversations about medical weight loss in the UK, and they’re frequently used interchangeably despite being genuinely different medications with different mechanisms, licensing, and availability. Here’s how they actually compare.
The Mechanism Differences
Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist that slows gastric emptying, reduces appetite, and improves insulin sensitivity. They’re the same active ingredient at different doses and with different licensing: Ozempic is licensed in the UK for type 2 diabetes management, while Wegovy is licensed specifically for weight management at doses generally higher than those used for diabetes treatment.
Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP receptors rather than GLP-1 alone. This dual mechanism is why Weight Loss Injections / Mounjaro has shown, in head-to-head trial data, generally greater average weight loss than semaglutide-based medications, though individual response varies considerably and trial averages don’t predict any one person’s result.
UK Licensing and Availability
All three require a prescription in the UK, whether through the NHS (with restricted eligibility criteria, typically requiring a higher BMI threshold combined with existing weight-related health conditions) or private prescription following a proper clinical assessment. Availability has fluctuated significantly since these medications went viral, with periodic UK-wide supply shortages affecting all three brands at different points — a genuine practical consideration alongside the clinical comparison, since a medication that’s theoretically the best fit isn’t useful if it’s unavailable.
Side Effect Profiles
All three share a broadly similar side-effect profile given their related mechanisms: nausea, particularly during dose escalation, along with potential constipation, diarrhoea, and fatigue. Tirzepatide’s dual mechanism means Mounjaro’s side-effect profile is similar but not identical to semaglutide’s, and individual tolerance varies enough that neither medication is reliably “gentler” for any given person — this is precisely why proper clinical supervision during dose titration matters regardless of which medication is prescribed.
Cost in the UK Private Market
Private pricing shifts frequently and varies by provider, dose, and whether the cost includes clinical consultation and monitoring, but broadly, tirzepatide-based Mounjaro has often carried a modestly higher monthly cost than semaglutide-based options at comparable treatment stages, reflecting both its dual mechanism and its generally stronger average efficacy data. Anyone comparing costs should look specifically at what’s included — unmonitored, consultation-free supply is a red flag regardless of price, given the genuine importance of dose titration and monitoring with these medications.
What Changes After Significant Weight Loss
Rapid, substantial weight loss commonly leaves loose or lax skin, particularly on the face, neck, and torso, simply because skin doesn’t always retract at the same rate fat is lost. This has made complementary treatments increasingly relevant alongside GLP-1 medication use: Skin Tightening Treatments and broader Skin Rejuvenation protocols are increasingly booked by patients partway through or after a significant weight-loss course, and Skin Boosters alongside Hyaluronic Acid Products support skin elasticity and hydration throughout the process, which some clinicians believe helps skin adapt more gracefully to rapid change.
The Takeaway
Mounjaro, Ozempic, and Wegovy are not interchangeable, despite frequently being discussed as though they are. Mounjaro’s dual mechanism has shown stronger average results in trial data, while semaglutide-based Ozempic and Wegovy remain well-established with a longer real-world track record. The right choice depends on individual health history, licensing eligibility, availability, and a proper clinical assessment — not brand recognition or social media buzz.
This article is for general information only and isn’t a substitute for individual medical advice. Anyone considering these medications should be assessed and monitored by a qualified prescriber.
